Stockscreener 앱 받기
4.57
1.33%
0.06
전일 마감가:
$4.51
열려 있는:
$4.51
하루 거래량:
23,587
Relative Volume:
0.11
시가총액:
$42.87M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.44%
1개월 성능:
+8.81%
6개월 성능:
-79.90%
1년 성능:
+0.00%
1일 변동 폭
$4.50
$4.66
1주일 범위
$4.25
$4.752
52주 변동 폭
$3.74
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
명칭
Tvardi Therapeutics Inc
전화
(713) 489-8654
주소
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
TVRD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
4.57 | 42.31M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-14 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-10-14 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-10-13 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | 개시 | Raymond James | Outperform |
| 2025-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 개시 | Piper Sandler | Overweight |
| 2025-05-21 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 개시 | BTIG Research | Buy |
| 2024-06-13 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | 다운그레이드 | Needham | Buy → Hold |
| 2024-06-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-03-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-11-01 | 재개 | Canaccord Genuity | Buy |
| 2021-08-03 | 개시 | JP Morgan | Neutral |
| 2020-04-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-29 | 재확인 | Laidlaw | Buy |
| 2019-02-06 | 재개 | Jefferies | Buy |
| 2019-01-15 | 개시 | BofA/Merrill | Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Jefferies | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-12 | 재개 | H.C. Wainwright | Buy |
| 2018-02-12 | 업그레이드 | Janney | Neutral → Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
모두보기
Tvardi Therapeutics Inc 주식(TVRD)의 최신 뉴스
Tvardi Therapeutics, Inc. Updates on Clinical Trials and Pipeline Progress - TradingView — Track All Markets
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Average Recommendation of “Hold” by Brokerages - Defense World
Why retail investors favor Tvardi Therapeutics Inc. stockQuarterly Growth Report & Low Volatility Stock Suggestions - Улправда
Will Tvardi Therapeutics Inc. (69C) stock gain from green policies2025 Technical Patterns & Expert Approved Trade Ideas - Улправда
Tvardi reports improved fibrosis scores with TTI-101 in IPF trial - Investing.com Nigeria
Will Tvardi Therapeutics Inc. stock split attract more investorsWeekly Gains Summary & Technical Buy Zone Confirmation - Улправда
Can Tvardi Therapeutics Inc. stock outperform in 2025 bull market2025 Support & Resistance & Low Volatility Stock Suggestions - Улправда
Will Tvardi Therapeutics Inc. stock recover faster than peersPortfolio Performance Report & Free Technical Confirmation Trade Alerts - Улправда
Can Tvardi Therapeutics Inc. (69C) stock stage a strong rebound this quarterWeekly Investment Report & Weekly High Return Forecasts - Улправда
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Risk Analysis: Will Tvardi Therapeutics Inc. stock split attract more investorsInflation Watch & Real-Time Stock Movement Alerts - Улправда
Why Tvardi Therapeutics Inc stock is seen as undervaluedWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - moha.gov.vn
Tvardi Therapeutics TTI-101 shows 9.4% fibrosis score decrease versus 2.4% placebo - marketscreener.com
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights - The Manila Times
MSN Money - MSN
Street Watch: Can Tvardi Therapeutics Inc stock outperform in 2025 bull marketWeekly Risk Report & Safe Capital Investment Plans - Bộ Nội Vụ
Tvardi Therapeutics (NASDAQ:TVRD) Upgraded at Wall Street Zen - Defense World
Will Q4 Earnings Be a Catalyst for Cubex Tubings LimitedEconomic Data Impact & Free Hedging Tactics for Volatile Markets - earlytimes.in
Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today? - MSN
Tvardi Therapeutics, Inc. (TVRD) Total Expenses (TTM) - Zacks Investment Research
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
What drives Tvardi Therapeutics Inc. (69C) stock priceEarnings Volatility Patterns & Capitalize On Momentum - earlytimes.in
Tvardi Therapeutics (NASDAQ:TVRD) Stock Rating Lowered by Wall Street Zen - Defense World
What drives Tvardi Therapeutics Inc 69C stock priceLarge Cap Stability Picks & Low Cost Stock Ideas - earlytimes.in
INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - TMX Newsfile
Pittsburgh Post-GazetteTvardi Therapeutics, Inc.Common Stock (Nasdaq:TVRD) Stock Quote - FinancialContent
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - FinancialContent
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - GuruFocus
Tvardi Therapeutics (NASDAQ:TVRD) Rating Increased to Hold at Wall Street Zen - Defense World
SHAREHOLDER INVESTOR REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
Can Tvardi Therapeutics Inc. stock sustain market leadershipPortfolio Value Summary & Low Risk High Win Rate Picks - Bölüm Sonu Canavarı
Will Tvardi Therapeutics Inc. stock see insider buyingIPO Watch & Weekly Market Pulse Updates - Улправда
Tvardi Therapeutics grants retention stock options and adopts new severance plan - Investing.com Nigeria
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
Tvardi Therapeutics Earnings Notes - Trefis
What analysts say about Tvardi Therapeutics Inc stockCash Flow Trends & Affordable Portfolio Growth - earlytimes.in
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials - MSN
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - TMX Newsfile
Tvardi Therapeutics (TVRD) Price Target Decreased by 24.64% to 15.15 - MSN
How Low Can Tvardi Therapeutics Stock Really Go? - Trefis
Tvardi Therapeutics Inc (TVRD) 재무 분석
Tvardi Therapeutics Inc (TVRD)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Tvardi Therapeutics Inc 주식 (TVRD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Feb 28 '25 |
Sale |
4.76 |
163 |
776 |
7,190 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 04 '25 |
Sale |
4.72 |
372 |
1,756 |
13,692 |
4.73%
0.92%
자본화:
|
볼륨(24시간):